Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

September 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

September 01, 2024

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

News Daily News

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

July 02, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

Semaglutide Has Similar Benefits in Women and Men With HFpEF

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

June 26, 2024

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

News Conference News ACC 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

April 01, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

February 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

February 01, 2024

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

News Daily News

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

January 11, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.